JP6441828B2 - 安定なグルコキナーゼ活性化剤組成物 - Google Patents
安定なグルコキナーゼ活性化剤組成物 Download PDFInfo
- Publication number
- JP6441828B2 JP6441828B2 JP2015561468A JP2015561468A JP6441828B2 JP 6441828 B2 JP6441828 B2 JP 6441828B2 JP 2015561468 A JP2015561468 A JP 2015561468A JP 2015561468 A JP2015561468 A JP 2015561468A JP 6441828 B2 JP6441828 B2 JP 6441828B2
- Authority
- JP
- Japan
- Prior art keywords
- cyclohexyl
- acetic acid
- ureido
- propoxy
- trans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772022P | 2013-03-04 | 2013-03-04 | |
| US61/772,022 | 2013-03-04 | ||
| PCT/US2014/019349 WO2014137797A2 (en) | 2013-03-04 | 2014-02-28 | Stable glucokinase activator compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513625A JP2016513625A (ja) | 2016-05-16 |
| JP2016513625A5 JP2016513625A5 (enExample) | 2018-06-28 |
| JP6441828B2 true JP6441828B2 (ja) | 2018-12-19 |
Family
ID=50424705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561468A Expired - Fee Related JP6441828B2 (ja) | 2013-03-04 | 2014-02-28 | 安定なグルコキナーゼ活性化剤組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160015638A1 (enExample) |
| EP (1) | EP2964198A2 (enExample) |
| JP (1) | JP6441828B2 (enExample) |
| KR (1) | KR20150123838A (enExample) |
| CN (1) | CN105050585A (enExample) |
| AU (1) | AU2014226290B2 (enExample) |
| CA (1) | CA2903433A1 (enExample) |
| HK (1) | HK1213780A1 (enExample) |
| IL (1) | IL240735A0 (enExample) |
| MX (1) | MX2015011109A (enExample) |
| WO (1) | WO2014137797A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102906077B (zh) | 2010-05-26 | 2015-03-04 | 转化技术制药有限责任公司 | 二甲双胍与葡萄糖激酶激活剂的联合使用以及包含二甲双胍和葡萄糖激酶激活剂的组合物 |
| KR102371364B1 (ko) | 2012-05-17 | 2022-03-07 | 브이티브이 테라퓨틱스 엘엘씨 | 당뇨병 치료를 위한 글루코키나아제 활성화제 조성물 |
| US11266630B2 (en) * | 2016-12-15 | 2022-03-08 | Hua Medicine (Shanghai) Ltd. | Oral preparation of glucokinase activator and preparation method therefor |
| JP2021526130A (ja) | 2018-06-12 | 2021-09-30 | ブイティーブイ・セラピューティクス・エルエルシー | インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用 |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| US11857536B2 (en) | 2020-06-04 | 2024-01-02 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| CA3185831A1 (en) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| US12479808B2 (en) | 2020-06-08 | 2025-11-25 | Vtv Therapeutics Llc | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
| CN116056760A (zh) * | 2020-06-08 | 2023-05-02 | 维特卫治疗有限责任公司 | {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 |
| KR20240084229A (ko) * | 2022-12-06 | 2024-06-13 | 유노비아 주식회사 | 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
| US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| ES2280582T3 (es) * | 2001-09-19 | 2007-09-16 | Elan Pharma International Limited | Formulaciones de insulina en nanoparticulas. |
| DE60325718D1 (de) * | 2002-05-06 | 2009-02-26 | Elan Pharma Int Ltd | Nystatin-nanopartikelzusammensetzungen |
| JP2005531606A (ja) * | 2002-06-10 | 2005-10-20 | エラン ファーマ インターナショナル,リミティド | ナノ粒子ステロール製剤およびステロールの組合せ |
| EP1511467A1 (en) * | 2002-06-10 | 2005-03-09 | Elan Pharma International Limited | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
| PL1723128T3 (pl) * | 2004-01-06 | 2013-04-30 | Novo Nordisk As | Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy |
| EA200701065A1 (ru) * | 2004-11-16 | 2007-12-28 | Элан Фарма Интернэшнл Лтд. | Инъецируемые составы, содержащие нанодисперсный оланзапин |
| UA89513C2 (uk) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
| JP2008524239A (ja) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミティド | ナノ粒子のタクロリムス製剤 |
| WO2006069098A1 (en) * | 2004-12-22 | 2006-06-29 | Elan Pharma International Ltd. | Nanoparticulate bicalutamide formulations |
| AU2006204083A1 (en) * | 2005-01-06 | 2006-07-13 | Elan Pharma International Ltd. | Nanoparticulate candesartan formulations |
| BRPI0608173A2 (pt) * | 2005-02-24 | 2010-11-09 | Elan Pharma Int Ltd | composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo |
| CN101175481A (zh) * | 2005-03-17 | 2008-05-07 | 伊兰制药国际有限公司 | 纳米颗粒免疫抑制化合物的可注射的组合物 |
| EP1865928A1 (en) * | 2005-03-17 | 2007-12-19 | Elan Pharma International Limited | Nanoparticulate biphosphonate compositions |
| WO2006110809A2 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
| AU2006336417A1 (en) * | 2005-05-10 | 2007-08-02 | Elan Pharma International, Limited | Nanoparticulate clopidogrel formulations |
| US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| US20060292214A1 (en) * | 2005-06-03 | 2006-12-28 | Elan Pharma International Limited | Nanoparticulate acetaminophen formulations |
| ATE459341T1 (de) * | 2005-06-03 | 2010-03-15 | Elan Pharma Int Ltd | Nanoteilchenförmige imatinib-mesylat- formulierungen |
| DE602006010070D1 (de) * | 2005-06-09 | 2009-12-10 | Elan Pharma Int Ltd | Nanopartikuläre ebastinformulierungen |
| CA2614412A1 (en) * | 2005-07-07 | 2007-01-18 | Elan Pharma International, Limited | Nanoparticulate clarithromycin formulations |
| US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
| EP2343053A1 (en) * | 2006-05-30 | 2011-07-13 | Elan Pharma International Limited | Nanoparticulate posaconazole formulations |
| WO2008066899A2 (en) * | 2006-11-28 | 2008-06-05 | Marinus Pharmaceuticals | Nanoparticulate formulations and methods for the making and use thereof |
| JP5419706B2 (ja) * | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| US20090028680A1 (en) * | 2007-07-27 | 2009-01-29 | Kling Troy L | Intermediate apparatus for towing utility vehicles |
| WO2009140624A2 (en) * | 2008-05-16 | 2009-11-19 | Takeda San Diego, Inc. | Glucokinase activators |
| US8054567B2 (en) * | 2008-07-23 | 2011-11-08 | Hitachi High-Technologies Corporation | Method for measuring write/read width of a composite magnetic head and a measuring device using the method |
| EP2442789A1 (en) * | 2009-06-18 | 2012-04-25 | Abbott Laboratories | Stable nanoparticulate drug suspension |
| RU2526914C2 (ru) * | 2009-06-19 | 2014-08-27 | Наноформ Хунгари Лтд. | Композиции телмисартана в форме наночастиц и способ их получения |
| CN101829061A (zh) * | 2010-05-14 | 2010-09-15 | 无锡纳生生物科技有限公司 | 一种紫杉醇纳米颗粒组合物及其制备方法 |
| CN102906077B (zh) * | 2010-05-26 | 2015-03-04 | 转化技术制药有限责任公司 | 二甲双胍与葡萄糖激酶激活剂的联合使用以及包含二甲双胍和葡萄糖激酶激活剂的组合物 |
-
2014
- 2014-02-28 KR KR1020157025036A patent/KR20150123838A/ko not_active Withdrawn
- 2014-02-28 HK HK16101756.4A patent/HK1213780A1/zh unknown
- 2014-02-28 CN CN201480011647.2A patent/CN105050585A/zh active Pending
- 2014-02-28 MX MX2015011109A patent/MX2015011109A/es unknown
- 2014-02-28 EP EP14714823.3A patent/EP2964198A2/en not_active Withdrawn
- 2014-02-28 CA CA2903433A patent/CA2903433A1/en not_active Abandoned
- 2014-02-28 AU AU2014226290A patent/AU2014226290B2/en not_active Expired - Fee Related
- 2014-02-28 WO PCT/US2014/019349 patent/WO2014137797A2/en not_active Ceased
- 2014-02-28 JP JP2015561468A patent/JP6441828B2/ja not_active Expired - Fee Related
-
2015
- 2015-08-20 IL IL240735A patent/IL240735A0/en unknown
- 2015-08-31 US US14/840,682 patent/US20160015638A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2964198A2 (en) | 2016-01-13 |
| JP2016513625A (ja) | 2016-05-16 |
| CN105050585A (zh) | 2015-11-11 |
| HK1213780A1 (zh) | 2016-07-15 |
| AU2014226290B2 (en) | 2018-11-15 |
| WO2014137797A2 (en) | 2014-09-12 |
| AU2014226290A1 (en) | 2015-10-08 |
| IL240735A0 (en) | 2015-10-29 |
| MX2015011109A (es) | 2015-11-16 |
| CA2903433A1 (en) | 2014-09-12 |
| WO2014137797A3 (en) | 2014-10-30 |
| US20160015638A1 (en) | 2016-01-21 |
| KR20150123838A (ko) | 2015-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6441828B2 (ja) | 安定なグルコキナーゼ活性化剤組成物 | |
| Gao et al. | Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs | |
| US20220233701A1 (en) | Solid compositions comprising a glucokinase activator and methods of making and using the same | |
| KR20100126452A (ko) | 난용성 약물용 약학적 조성물 | |
| CN100560067C (zh) | 盐酸决奈达隆口服药物组合物及其制备方法 | |
| WO2018108128A1 (zh) | 葡萄糖激酶激活剂的口服制剂及其制备方法 | |
| JP2021059551A (ja) | フェニルアミノピリミジン誘導体を含む医薬組成物 | |
| JP2010513356A (ja) | ニューロキニンアンタゴニストを含む製剤 | |
| JP2020518611A (ja) | 水溶解度及びバイオアベイラビリティが改善された組成物 | |
| TWI418370B (zh) | 溶出安定性製劑 | |
| TW201328703A (zh) | 粒子狀醫藥組成物 | |
| US11517569B2 (en) | Vilazodone inclusion complexes, compositions and preparation thereof | |
| CN114948969B (zh) | 包含化合物与富马酸的结晶形式的药物组合物及其制备方法和用途 | |
| WO2023098745A1 (zh) | 维拉佐酮组合物及其药物制剂、制备方法和用途 | |
| WO2017061431A1 (ja) | ソリスロマイシンを含む錠剤 | |
| US20090012146A1 (en) | Solubility-enhanced pharmaceutical compositions comprising zafirlukast | |
| US12171761B2 (en) | Vilazodone inclusion complexes, compositions and preparation thereof | |
| TW201924661A (zh) | 含有非馬沙坦的固體分散體 | |
| TW202227049A (zh) | 鹽酸決奈達隆藥物組合物、其製備方法及應用 | |
| WO2023034844A1 (en) | Delayed release niclosamide formulation | |
| CN116687961A (zh) | 一种含有兰索拉唑及碳酸氢钠的干混悬剂及其制备方法 | |
| WO2005023225A1 (en) | Cilostazol adsorbate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151027 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170228 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171106 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180507 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20180507 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181024 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181122 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6441828 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |